Where the safety data comes from

Every CE-marked Class III medical device sold in Europe must be supported by a Clinical Evaluation Report — a mandatory regulatory submission, not a voluntary marketing document. ChondroFiller® liquid sits in Class III, the strictest device category under European medical law, reserved for products that are implanted or injected into the body and whose failure carries serious clinical consequence. That regulatory obligation is why a consolidated safety and performance dataset exists at all.

The most recent version, CER Version 09 (dated 30 April 2025), was compiled by Meidrix Biomedicals GmbH, the device manufacturer. It draws together findings from multiple clinical investigations into a single record reviewed by EU notified-body assessors. As the most comprehensive consolidated source available, it provides the evidence base for the figures discussed throughout this article.

One interpretive point matters here: because the CER is manufacturer-sponsored, the manufacturer controls which investigations are assembled and how data are presented. An independent systematic review — were one available — might surface studies with different patient profiles or longer follow-up, potentially narrowing the confidence intervals around the headline safety figures. For now, the CER represents the best available record; readers should weigh it with that sponsorship context in mind.

Treatments performed and reported complaint rate

Published post-market surveillance data within CER Version 09 record more than 19,000 ChondroFiller® liquid treatments performed globally — a real-world volume that gives the accompanying adverse-event figures meaningful scale.

Across that body of experience, the overall reported complaint rate sits at approximately 0.06%. Fewer than one in every 1,500 treatments generated a reported complaint of any kind. Separately, pooled clinical study data put the rate of device-related complications at approximately 0% in well-selected patients — those treated for focal Grade III/IV defects with healthy surrounding cartilage borders.

The distinction between those two figures is worth holding. Complaint rate captures all communications across the post-market surveillance network — transient symptoms, procedural queries, packaging concerns — whereas device-related complication rate reflects clinically adjudicated adverse events. That the latter sits at approximately zero across a dataset of this size suggests the biocompatibility profile observed in the clinical investigations extends into routine outpatient practice.

Functional improvement: what IKDC scores report

The International Knee Documentation Committee score — IKDC for short — is a standardised questionnaire measuring knee function, symptoms, and quality of life on a scale of 0 to 100. For a score change to represent something patients actually notice in daily life, it must clear the minimum clinically important difference (MCID): the threshold, established in the literature at 16.7 points, below which statistical movement may not translate into meaningful functional gain.

Across four separate knee clinical studies compiled in the CER, ChondroFiller® liquid consistently exceeded that threshold. Published series report IKDC improvements of approximately 30 points — roughly double the MCID — in patients treated for focal Grade III/IV defects. The most durably characterised dataset comes from the prospective PMCF study by Jerosch et al., in which patients recorded a mean IKDC improvement of 32.4 points sustained at three-year follow-up, reaching a functional endpoint score of 80. That represents the longest follow-up in the current knee dataset rather than a definitive long-term ceiling, but the sustained trajectory is a meaningful signal that early gains were not simply transient.

Beyond the knee, clinical trial data indicate the scaffold has been evaluated in other joints at longer horizons. Hip studies tracked patients to six years and observed an 81% rate of good or excellent outcomes alongside significant clinical improvement. Wrist feasibility data — from a prospective study in patients with post-fracture residual defects — show MRI-confirmed reduction in bone marrow oedema and significant improvements in both NRS pain scores and DASH functional scores. These findings extend the dataset rather than establish equivalence with the knee programme.

Structural repair: MOCART scores and scaffold maturation

MOCART — Magnetic Observation of Cartilage Repair Tissue — is an MRI-based scoring system used to assess how well a repaired cartilage defect fills and integrates with the surrounding native tissue. Scores range from 0 to 100, with higher values indicating more complete fill and better structural continuity at the repair margin.

Across European knee studies compiled in the CER, ChondroFiller® liquid produced MOCART scores of 81.6–84.3, indicating greater than 80% defect fill with good native-cartilage integration. One study provides a particularly instructive trajectory: a mean MOCART of 65.3 at four weeks rising to 81.6 at twelve months. That progression matters because it shows the scaffold continues to consolidate structurally well after the initial outpatient injection — repair is an ongoing biological process rather than an immediate result.

Laboratory research published in 2025 offers a mechanistic view of why that maturation occurs. An ex vivo osteochondral model found a 2.4-fold increase in DNA content by day 14 in ChondroFiller-treated defects compared with untreated controls. DNA content serves as a proxy for cellular activity within the scaffold. The finding suggests the scaffold may support active host-cell recruitment into the defect space, rather than simply occupying it as a passive filler — though this remains laboratory evidence and does not constitute proof of cartilage regrowth in patients.

Complication and reoperation rates against surgical comparators

Patients weighing an injectable scaffold against established surgical routes often want a direct comparison on risk and reoperation. Published literature cited within the manufacturer's clinical evaluation record offers the following figures: microfracture carries a complication rate of 0–7% and a reoperation rate of up to 41%; ACI/MACI procedures show complications in up to 17% of cases and reoperation rates of up to 37%. Against those benchmarks, ChondroFiller® liquid's pooled complication rate of approximately 0% and reoperation rate of 3–8% compare favourably on both measures.

The sourcing of these figures carries an important caveat: the surgical comparator data are drawn from the same manufacturer CER rather than from a head-to-head independent trial. That limits interpretive weight — the contrast is contextually informative but does not constitute comparative clinical evidence in the formal sense. An independent randomised study comparing ChondroFiller directly with microfracture or ACI/MACI has not yet been published at the time of writing.

Within those limits, the figures remain a useful frame for patients in the pre-decision stage. The reoperation gap between ChondroFiller and microfracture in particular — 3–8% versus up to 41% — is large enough to be clinically meaningful even allowing for the methodological caveat, and it reflects the simpler, single-stage nature of an injectable scaffold pathway compared with procedures that may require repeat intervention.

What the evidence doesn't yet answer

Three clinical unknowns stand out for anyone weighing the published record against their own situation.

Defect size. The evidence base is strongest for focal defects up to approximately 3 cm². For larger defects, data remain limited relative to established cell-based programmes such as ACI/MACI, where longer track records exist at greater surface areas. Patients with more extensive cartilage loss may find the current literature less directly applicable to their case.

Follow-up horizon. The longest available knee follow-up reaches three years in the Jerosch et al. prospective study; hip data extend to six years, where an 81% good or excellent outcome rate has been reported. What happens beyond that window — whether repair tissue remains durable at ten or fifteen years — has not yet been captured in published series. For a younger, active patient making a decision intended to last decades, that gap is worth discussing explicitly at a clinical assessment.

Regulatory access. ChondroFiller® liquid holds CE marking as a Class III device in Europe but does not currently have FDA approval in the United States. In the UK it is not routinely funded by the NHS; access is self-funded through private appointments, with published costs from approximately £3,000 per box.

The follow-up horizon is the most practically relevant of these unknowns for someone deciding now. The three-to-six-year dataset is promising, but long-term durability evidence is still accumulating — and that is the honest framing any clinical assessment should offer alongside the safety and functional data already described.